Figure 6
Survival curve for 86 T-PLL patients treated with alemtuzumab. Survivors beyond 72 months are those who received consolidation with a HSCT.
Survival curve for 86 T-PLL patients treated with alemtuzumab. Survivors beyond 72 months are those who received consolidation with a HSCT.
